CEL-SCI Conducts Meeting of North American Clinical Centers to Support Success of Its Phase III Cancer Trial with Multikine
CEL-SCI Corporation announced that it has held the Investigator Meeting for the North American clinical investigators participating in the ongoing international Phase III clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Inj.). Investigators from 14 clinical centers in Canada and the U.S who are participating in the Phase III clinical trial for head and neck cancer were in attendance. The Investigator Meeting for the 56 clinical centers in Europe that are participating in the study was held...
View full press release